Literature DB >> 27535391

Treatment: Radiation Therapy.

Sagus Sampath1.   

Abstract

Radiation therapy (RT) is an integral part of treating all stages of lung cancer. Stereotactic ablative radiation therapy (SABR) has emerged as a standard treatment option for stage I-II patients with medically inoperable disease. Stage IIIA-IIIB disease is typically managed with definitive concurrent chemo-radiotherapy (CRT). Intensity modulated radiation therapy (IMRT) has enabled delivery of more potent RT dose while greatly limiting dose to surrounding normal organs, including lung, esophagus, and heart. SABR may have an expanding role in the treatment of stage IV patients, with new clinical trials exploring its combination with systemic immuotherapies.

Entities:  

Keywords:  Chemoradiation; Lung cancer; Oligometastases; Radiation; SABR; Stereotactic

Mesh:

Year:  2016        PMID: 27535391     DOI: 10.1007/978-3-319-40389-2_5

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  10 in total

1.  Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study.

Authors:  Yun Bai; Xian-Shu Gao; Shang-Bin Qin; Jia-Yan Chen; Meng-Meng Su; Qing Liu; Xiu-Bo Qin; Ming-Wei Ma; Bo Zhao; Xiao-Bin Gu; Mu Xie; Ming Cui; Xin Qi; Xiao-Ying Li
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

2.  Image-guided selection of Gd@C-dots as sensitizers to improve radiotherapy of non-small cell lung cancer.

Authors:  Xiaofen Ma; Chaebin Lee; Tao Zhang; Jinghua Cai; Hui Wang; Fangchao Jiang; Zhanhong Wu; Jin Xie; Guihua Jiang; Zibo Li
Journal:  J Nanobiotechnology       Date:  2021-09-22       Impact factor: 10.435

3.  miR-3648 promotes lung adenocarcinoma-genesis by inhibiting SOCS2 (suppressor of cytokine signaling 2).

Authors:  Yanhong Tu; Fan Mei
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

4.  microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.

Authors:  Kexin Jiang; Huawei Zou
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

5.  The Prognostic Value of Multiple Systemic Inflammatory Biomarkers in Preoperative Patients With Non-small Cell Lung Cancer.

Authors:  Kai Wang; Qidi Zhao; Tao Yan; Deyu Guo; Jichang Liu; Guanghui Wang; Jiajun Du
Journal:  Front Surg       Date:  2022-04-04

6.  Myeloid-Derived Suppressor Cells and CD68+CD163+M2-Like Macrophages as Therapeutic Response Biomarkers Are Associated with Plasma Inflammatory Cytokines: A Preliminary Study for Non-Small Cell Lung Cancer Patients in Radiotherapy.

Authors:  Minghe Lv; Xibing Zhuang; Shali Shao; Xuan Li; Yunfeng Cheng; Duojiao Wu; Xiangdong Wang; Tiankui Qiao
Journal:  J Immunol Res       Date:  2022-07-26       Impact factor: 4.493

7.  Effects of Ultrafine Single-Nanometer Oxygen Bubbles on Radiation Sensitivity in a Tumor-Bearing Mouse Model.

Authors:  Navchaa Gombodorj; Takehiko Yokobori; Nobutoshi Mutsuki; Bilguun Erkhem-Ochir; Haruka Okami; Takayuki Asao; Hiroshi Saeki; Ken Shirabe; Dai Yamanouchi
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

8.  Analysis of prognosis and treatment decisions for patients with second primary lung cancer following esophageal cancer.

Authors:  Jin-Luan Li; Hui Li; Qian Wu; Han Zhou; Yi Li; Yong-Heng Li; Jiancheng Li
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

9.  Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis.

Authors:  Tao Cheng; Zhiheng Zhang; Hua Shen; Ziying Jian; Junsheng Li; Yujun Chen; Yi Shen; Xinyi Dai
Journal:  J Nanobiotechnology       Date:  2020-09-05       Impact factor: 10.435

10.  Predictors and survival of primary clear cell carcinoma of liver: a population-based study of an uncommon primary liver tumor.

Authors:  Jie Wen; Xueyan Yao; Abudureyimujiang Aili; Lixiang Xue; Junjie Wang
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.